Halozyme Therapeutics, Inc. (HALO) Stock Price & News

Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia

About Halozyme Therapeutics, Inc.

CEOHelen I. Torley

Employees423

Founded1998

HeadquartersSan Diego, Kalifornië, Verenigde State van Amerika

Sector-

Websitehalozyme.com

All values in USD	Sep. 2025	Des. 2025	Mrt. 2026	Jun. 2026
Revenue	354,26 m	451,77 m	376,71 m	481,00 m
Cost of goods sold	72,49 m	110,67 m	104,80 m	106,84 m
Cost of revenue	72,49 m	110,67 m	104,80 m	106,84 m
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	46,09 m	63,33 m	57,88 m	57,00 m
Operating expense	63,85 m	86,70 m	87,39 m	86,51 m
Total operating expenses	136,34 m	197,37 m	192,19 m	193,34 m
Operating income	217,92 m	254,40 m	184,52 m	287,65 m
Other non operating income	-	-	-	-
EBT including unusual items	218,96 m	-100,85 m	180,33 m	284,90 m
EBT excluding unusual items	218,96 m	251,58 m	180,30 m	284,90 m
Income tax expense	43,73 m	40,74 m	30,28 m	54,99 m
Effective tax rate	19,97%	-40,40%	16,79%	19,30%
Other operating expenses	-	-	-	-
Net income	175,22 m	-141,59 m	150,05 m	229,91 m
Net profit margin	49,46%	-31,34%	39,83%	47,80%
Earnings per share	1,72	-0,24	1,60	2,28
Interest and investment income	5,33 m	2,09 m	1,29 m	2,84 m
Interest expense	-4,30 m	-4,91 m	-5,51 m	-5,59 m
Net interest expenses	1,04 m	-2,82 m	-4,22 m	-2,75 m
Depreciation and amortization charges	-	-	-	-
EBITDA	236,84 m	279,08 m	215,65 m	319,12 m
Gain or loss from assets sale	-	2,62 m	-	76,00 k

Ask anything